Prostate Cancer

Sleeping in at the weekend could add years to your life The are some surprising benefits to turning off your alarm after a hectic work week The are some surprising benefits to turning off your alarm after a hectic work week.

J&J's pharma business spurs sales growthStrong sales of Johnson & Johnson's cancer drugs and other medicines helped boost the company's revenue and earnings for the latest quarter, but the health-products giant's U.S. consumer business continued to struggle.

New research claims coffee isn’t bad for you, but should you drink 8 cups a day? You may be able to drink multiple cups of coffee a day without serious health risksYou may be able to drink multiple cups of coffee a day without serious health risks.

Sophiris Bio shares plummet 46% on news of patient death in trial for prostate cancer drugSophiris Bio Inc. shares plummeted nearly 46% in premarket trade on Monday after the company said that a patient had died in the company's ongoing phase 2b clinical trial for its prostate cancer drug topsalysin. The patient death happened the same day that the patient was administered the drug for the second time, the company said. Sophiris is investigating the death and won't administer the drug a second time for any more patients, as a precaution. The phase 2b trial is geared at evaluating how safe and tolerable one dose or, when applicable, two doses of topsalysin are for patients, and was the first such trial designed to allow certain patients to get a second administration of the drug. However, patients had to meet certain criteria, including no significant safety issues related to the drug and evidence of a response to the treatment. Total, 38 patients were enrolled in the trial, and 11 have already received a second dose. The company said that an independent data monitoring committee reviewed safety data, including data on the first seven patients who got a second dose of the drug, in May, and recommended the trial continue without any changes. Topsalysin is also in late-stage development for lower urinary tract symptoms of benign prostatic hyperplasia. Company shares have surged nearly 77% over the last three months, compared with a 6.4% rise in the S&P 500 and a 4.5% rise in the Dow Jones Industrial Average .

Sophiris Bio shares plummet 42% on news of patient death in trial for prostate cancer drug

UPDATE: Merck shares jump 7% on news of positive results from lung cancer trialMerck & Co. Inc. shares jumped almost 7% Tuesday, after the company announced positive results in a late-stage lung cancer trial. The New Jersey-based drug company said the Phase 3 trial of Keytruda in combination with pemetrexed and cisplatin or carboplatin for patients with metastatic non-squamous non-small cell lung cancer met its dual primary endpoints of overall survival and progression-free survival. Results from the Keynote-189 trial will be presented at a coming medical meeting and submitted to the regulator, said Merck. Non-small cell lung cancer is the most common of two types of lung cancer, which kills more people than colon, breast and prostate cancers combined. The news weighed on shares of Roche Holding AG , which is developing a rival drug. Merck shares have fallen about 6% in the last 12 months, while the S&P 500 has gained 22%.

How keeping these New Year’s resolutions could reduce your odds of getting cancer It pays to make good on your resolution past the month of JanuaryIt pays to make good on your resolution past the month of January.

Alabama Republican Congressman Mo Brooks announces he has prostate cancerRep. Mo Brooks, an Alabama Republican, announced Wednesday on the House floor that he has been diagnosed with "high-risk" prostate cancer. Brooks ran for Jeff Sessions' Senate seat but lost in a crowded Republican field to Roy Moore. Brooks said losing the Senate primary may have saved his life because he was able to have the test that detected his cancer.

This expert has a dire warning about not getting enough sleep Poor sleep is linked to Alzheimer’s disease, stroke, cancer and more, and it doesn’t take that much missed sleep Sleep expert Matthew Walker isn’t a fan of the expression “You can sleep when you’re dead.” In fact, he calls it “mortally unwise advice.”

Novartis to buy radio-pharma company for $3.9BNovartis AG has agreed to acquire Advanced Accelerator Applications SA for $3.9 billion, a deal that would boost its oncology portfolio as generic competition eats into sales of blockbuster blood-cancer drug Gleevec.

My father got married two months before he died and his new wife won’t return my calls This patriarch died without a will and left his son in financial limboThis patriarch died without a will and left his son in financial limbo.

Johnson & Johnson discards two hoped-for billion-dollar drugs The discontinuation comes at a time when drug companies are struggling with new competition for their established brandsThe company said in May that the two were among 11 ‘potential blockbuster’ drugs.

This drug may be able to treat both women’s health disorders and prostate cancer Myovant’s Relugolix could be effective in uterine fibroids, endometriosis and prostate cancer, diseases with large marketsIf successful, the drug should be safer, work better and be more convenient to take than current options, the company said.

Endocyte's stock rockets again on heavy volume after license deal for prostate cancer treatmentShares if Endocyte Inc. rocketed 49% on heavy volume Tuesday, and have not run up nearly four-fold this week, after the biopharmaceutical company announced a license agreement with ABX GmbH for a phase-3 ready treatment for prostrate cancer. Trading volume was 54.8 million shares in afternoon trade, enough to make the stock the most actively traded on the Nasdaq exchange. On Monday, the stock blasted off 157.5% on volume of 55.9 million shares. Under terms of the agreement, Endocyte has exclusive worldwide rights to develop and commercialize PSMA-617, in exchange for a $12 million upfront payment to ABX and potential milestone payments of up to $160 million. In addition, Endocyte has issued 2 million shares of its stock to ABX and issued a warrant for the purchase of up to 4 million additional shares. "This transaction is transformational to Endocyte, accelerating out path to commercialization," said Chief Executive Mike Sherman. "We intend to seek regulatory approval to initiate a Phase 3 registration trial of Lu-PSMA-617 in early 2018." The stock has now more than doubled year to date, while the iShares Nasdaq Biotechnology ETF has rallied 27% and the S&P 500 has gained 13%.

Congressman urges President Trump to take action on $90,000 multiple sclerosis drug Cummings said the president could ‘make a deal’ to lower Zinbryta’s priceU.S. prices of Zinbryta are higher than those in other countries, including 2.8 times higher than Norway and Denmark and 3.8 times higher than Switzerland.

Cancer vaccines, long considered failures, are hot again Recent scientific advances and cutting-edge cancer therapies are giving an old idea new lifeSuccessful sister fields of cancer research have spurred scientists and investors to give cancer vaccines another look.

More evidence coffee drinkers live longer — even those ordering decaf International Coffee Day: These studies find a link between caffeine and mortality ratesInternational Coffee Day: These studies find a link between caffeine and mortality rates.

What it takes to deliver a cancer therapy during a hurricane Prostate cancer vaccine Provenge follows a very specific schedule. Sometimes current events get in the way“Sometimes it means we have to hire private jets, or drive with a police escort to deliver things within minutes of expiration.”

Inovio shares jump 5% premarket after two peer-reviewed paper support its researchInovio Pharmaceuticals Inc. shares climbed about 5% in premarket trade Thursday, after the company said its DNA-based monoclonal antibody program (dMAb) has been boosted by two peer-reviewed scientific papers that show its impact on prostate tumors and in preventing infection from a pneumonia-creating bacteria in early stage studies. "These two newly published studies further support that Inovio's potent dMAb platform could be expanded to target cancer and bacterial diseases along with viral infectious diseases," Chief Executive Dr. Joseph Kim said in a statement. A paper published in the journal "Cancer Immunology, Immunotherapy" outlined how the dMAb shrunk prostate tumors in a preclinical animal model. Another paper showed that its dMAb constructs targeting antibiotic-resistant bacteria protected mice when challenged with a lethal dose of a pneumonia-creating bacteria. Inovio shares are down 13% in 2017 through Wednesday, while the S&P 500 has gained 12%.

Pfizer shares rise 1.4% after news of positive late-stage cancer trialPfizer Inc. shares rose as much as 1.4% in premarket trade Thursday on news that its late-stage clinical trial examining its key cancer drug Xtandi in non-metastatic castration-resistant prostate cancer met its primary endpoint. The trial, which was conducted with Astellas Pharma Inc. , found that Xtandi combined with with a standard prostate cancer therapy had improved metastasis-free survival relative to the standard prostate cancer therapy on its own. Xtandi is already FDA-approved for metastatic castration-resistant prostate cancer; the results could potentially allow for the expansion of Xtandi's label to cover all patients with castration-resistant prostate cancer, the companies said. There are currently no FDA-approved treatments for patients with this type of prostate cancer until they develop confirmed radiographic metastatic disease, according to Carolina Urologic Research Center's Dr. Neal Shore. Pfizer shares have risen 7.3% over the last three months, compared with a 2.5% rise in the S&P 500 .

Aptevo shares more than double on end of drug partnership, sale of marketed drugsShares of Aptevo Therapeutics Inc. more than doubled late Thursday after the tiny Seattle-based biotech company said it ended a partnership with German biotech company MorphoSys AG for a prostate cancer drug candidate and plans to develop the drug on its own. Aptevo shares soared 134% to $3.11 after hours. Aptevo said it ended a commercialization and development partnership with MorphoSys and plans to advance the drug APVO414 through early-stage clinical trials for the treatment of metastatic castration resistant prostate cancer. Separately, Aptevo said it's agreed to sell three of its marketed products to Saol Therapeutics for $65 million, plus milestone payments and accounts receivable payments of up to $9.5 million. Those products are WinRho SDF for autoimmune platelet disorder, Hepatitis B drug HepaGam B and varicella zoster virus treatment Varizig.

Immune Design’s quest for a cancer vaccine could go the distance The company’s cancer vaccine approach ‘mimics the natural generation of protective immunity,’ said a Leerink analystDeveloping a cancer vaccine is a tricky business, but Immune Design Corp.’s efforts could be the exception.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.